Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport
A Phase 1, Open-Label, Fixed Sequence, Drug-Drug Interaction Study to Evaluate the Effects of Repeat Titrated Doses of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport in Healthy Subjects
Sponsor: Emalex Biosciences Inc.
This PHASE1 trial investigates Drug Interaction and is currently completed. Emalex Biosciences Inc. leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
First recorded
Apr 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Emalex Biosciences Inc.
- ICON Early Phase Services
- Nuventra, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .